Heparin reduces glomerular infiltration and TGF-β protein expression by macrophages in puromycin glomerulosclerosis

Journal of Nephrology

Volumn 16, Issue 2, 2003, Pages 210-218

  Ceol, Monica ^a,b   Vianello, Daniela ^a   Schleicher, Erwin ^b   Anglani, Franca ^a   Barbanti, Miriam ^c   Bonfante, Luciana ^a   Bertaglia, Giselda ^a   Graziotto, Romina ^a   D'Angelo, Angela ^a   Del Prete, Dorella ^a   Gambaro, Gioanni ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Alfa Wassermann SpA   (Italy)

Author keywords

Galacturonil glycosaminoglycan; Glomerulosclerosis; Heparin; Macrophage; Sulodexide; TGF

Indexed keywords

ALBUMIN; COLLAGEN TYPE 4; HEPARIN; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; MONOCLONAL ANTIBODY; PROTEIN; PUROMYCIN; SODIUM CHLORIDE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COMPOSITION; CELL COUNT; CELL INFILTRATION; CONTROLLED STUDY; CYTOPLASM; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG STRUCTURE; EXTRACELLULAR MATRIX; FOAM CELL; GLOMERULAR DYSFUNCTION; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; KIDNEY DISEASE; MACROPHAGE; MALE; MESANGIUM; NONHUMAN; PROTECTION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; PROTEIN URINE LEVEL; RAT; REGULATORY MECHANISM; TREATMENT OUTCOME; ANALYSIS OF VARIANCE; ANIMAL; BIOSYNTHESIS; CELL CULTURE; COMPARATIVE STUDY; DISEASE MODEL; DOSE RESPONSE; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; METABOLISM; NEEDLE BIOPSY; PATHOLOGY; PROBABILITY; SENSITIVITY AND SPECIFICITY; WISTAR RAT;

ANALYSIS OF VARIANCE; ANIMALS; BIOPSY, NEEDLE; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLOMERULAR FILTRATION RATE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HEPARIN; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MALE; PROBABILITY; PUROMYCIN; RATS; RATS, WISTAR; SENSITIVITY AND SPECIFICITY; TRANSFORMING GROWTH FACTOR BETA;

EID: 0042521148     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Coffey AK, Karnovsky MJ. Heparin inhibits mesangial cell proliferation in Habu-venom-induced glomerular injury. Am J Pathol 1985; 120: 248-55.
2. Floege J, Eng E, Young BA, Couser WG, Johnson RJ. Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis. Kidney Int 1993; 43: 369-80.
3. Olson JL. Role of heparin as a protective agent following reduction of renal mass. Kidney Int 1984; 25: 376-82.
4. Purkerson ML, Tollefsen DM, Klahr S. N-desulfated/acetylated heparin ameliorates the progression of renal disease in rats with subtotal renal ablation. J Clin Invest 1988; 81: 69-74.
5. Diamond JR, Karnovsky MJ. Non-anticoagulant protective effect of heparin in chronic aminonucleoside nephrosis. Ren Physiol 1986; 9: 366-74.
6. Gambaro G, Venturini AP, Noonan DM, Fries W, Re G, Garbisa S, Milanesi C, Pesarini A, Borsatti S, Marchi E, Baggio B. Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int 1994; 46: 797-806.
7. Peten EP, He CJ, Patel A, Yang CW, Striker GF, Striker LJ. Non-anticoagulant heparin suppresses α1 type I collagen mRNA and reduces laminin B1 mRNA expression in sclerotic glomeruli from mice transgenic for growth hormone (GH) mice [Abstract]. J Am Soc Nephrol 1993; 4: 780.
8. Myrup B, Hansen PM, Jensen T, Kofoed-Enevoldsen A, Feldt-Rasmussen B, Gram J, Kluft C, Jespersen J, Deckert T. Effect of low-dose heparin on urinary albumin excretion in insulin-dependent diabetes mellitus. Lancet 1995; 345: 421-2.
9. Tamsma JT, Van Der Woude FJ, Lemkes HHPJ. Effect of sulfated glycosaminoglycans on albuminuria in patients with overt diabetic (type-1) nephropathy. Nephrol Dial Transplant 1996; 11: 182-5.
10. GambaroG, Kinalska I, Oksa A, Pont'uch P, Hertlova M, Olsovsky J, Manitius J, Fedele D, Czekalski S, Perusicova J, Skrha J, Taton J, Grzeszczak W, Crepaldi G. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: The Di.N.A.S. randomized trial. J Am Soc Nephrol 2002; 13: 1615-25.
11. Solini A, Vergnani L, Ricci F, Crepaldi G. Glycosaminoglycans delay the progression of nephropathy in NIDDM. Diabetes Care 1997; 20: 813-7.
12. Van Der Pijl JW, Van Der Woude FJ, Geelhoed-Duijvestijn PH, Fröhlich M, Van Der Meer FJ, Lemkes HH, Van Es LA. Danaparoid sodium lowers proteinuria in diabetic nephropathy. J Am Soc Nephrol 1997; 8: 456-62.
13. Castellot JJ, Hoover RL, Harper PA, Karnowsky MJ. Heparin and glomerular epithelial cell-secreted heparin-like species inhibit mesangial cell proliferation. Am J Pathol 1985; 120: 427-35.
14. Gambaro G, Barbanti M, Marchi E, Baggio B. Therapy with glycosaminoglycans in nephrology, In Harenberg J, Casu B eds. Nonanticoagulant Actions of Glycosaminoglycans. New York: Plenum Press 1996; 281-6.
15. Ceol M, Gambaro G, Sauer U, Baggio B, Anglani F, Forino M, Facchin S, Bordin L, Weigert C, Nerlich A, Schleicher ED. Glycosaminoglycan therapy prevents TGF-β1 overexpression and pathologic changes in renal tissue of long-term diabetic rats. J Am Soc Nephrol 2000; 11: 2324-36.
16. Harris KP, Lefkowith JB, Klahr S, Schreiner GF. Essential fatty acid deficiency ameliorates acute renal dysfunction in the rat after the administration of the aminonucleoside of puromycin. J Clin Invest 1990; 86: 1115-23.
17. Saito T, Atkins RC. Contribution of mononuclear leukocytes to the progression of experimental focal glomerular sclerosis. Kidney Int 1990; 37: 1076-83.
18. Diamond JR, Pesek-Diamond I. Sublethal X-irradiation during acute puromycin nephrosis prevents late renal injury. Am J Physiol 1991; 260: F779-86.
19. Diamond JR, Ding G, Frye J, Pesek-Diamond I. Glomerular macrophages and the mesangial proliferative response in the experimental nephrotic syndrome. Am J Pathol 1992; 141: 887-94.
20. Floege J, Alpers CE, Burns MW, Pritzl P, Gordon K, Couser WG, Johnson RJ. Glomerular cells, extracellular matrix accumulation, and the development of glomerulosclerosis in the remnant kidney model. Lab Invest 1992; 66: 485-97.
21. Van Goor H, Van Der Horst ML, Fidler V, Grond J. Glomerular macrophage modulation affects mesangial expansion in the rat after renal ablation. Lab Invest 1992; 66: 564-71.
22. Pesek-Diamond I, Ding G, Frye J, Diamond JR. Macrophages mediate adverse effects of cholesterol feeding in experimental nephrosis. Am J Physiol 1992; 263: F776-83.
23. Nikolic-Paterson DJ, Lan HY, Prudence AH, Atkins RC. Macrophages in renal injury. Kidney Int 1994; 45 (suppl): S79-82.
24. Eddy AA. Interstitial macrophages as mediators of renal fibrosis. Exp Nephrol 1995; 3: 76-9.
25. Ding G, Van Goor H, Frye J, Diamond JR. Transforming growth factor-beta expression in macrophages during hypercholesterolemic states. Am J Physiol 1994; 267: F937-43.
26. Diamond JR, Pesek I, Karnovsky MJ. Exacerbation of chronic aminonucleoside nephrosis by dietary cholesterol supplementation. Kidney Int 1987; 33: 917-24.
27. Diamond JR, Pesek I, McCarter MD, Karnovsky MJ. Altered functional characteristics of rat macrophages during nephrosis. Synergistic effects of hypercholesterolemia. Am J Pathol 1989; 135: 711-8.
28. Laurell CB. Antigen antibody crossed electrophoresis. Anal Biochem 1965; 10: 358-61.
29. Nerlich AG, Schleicher ED, Wiest I, Specks U, Timpl R. Immunohistochemical localization of collagen VI in diabetic glomeruli. Kidney Int 1994; 45: 1648-56.
30. Ceol M, Nerlich A, Baggio B, Anglani F, Sauer U, Schleicher E, Gambaro G. Increased glomerular α1(IV) collagen expression and deposition in long-term diabetic rats is prevented by chronic glycosaminoglycan treatment. Lab Invest 1996; 74: 484-95.
31. Dijkstra CD, Kopp EA, Joling P, Krall G. The heterogeneity of mononuclear phagocytes in lymphoid organs. Distinct macrophage subpopulations in the rat recognized by monoclonal antibodies ED-1, ED-2, and ED-3. Immunology 1985; 54: 589-99.
32. Miyazono K, Olofsson A, Colosetti P, Heldin CH. A role of the latent TGF-β1 binding protein in the assembly and secretion of TGF-β1. EMBO J 1991; 10: 1091-101.
33. Raij L, Azar S, Keane W. Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int 1984; 26: 137-43.
34. Ding G, Pesek-Diamond I, Diamond JR. Cholesterol, macrophages, and gene expression of TGF-β1 and fibronectin during nephrosis. Am J Physiol 1993; 33: F577-84.
35. Khalil N, Bereznay O, Sporn M, Greenberg AH. Macrophage production of transforming growth factor β and fibroblast collagen synthesis in chronic pulmonary inflammation. J Exp Med 1989; 170: 727-37.
36. Gambaro G, Baggio B. Glycosaminoglycans: A new paradigm in the prevention of proteinuria and progression of glomerular disease. Nephrol Dial Transplant 1996; 11: 762-4.
37. Brady HR. Leukocyte adhesion molecules and kidney diseases. Kidney Int 1994; 45: 1285-300.
38. Webb LM, Ehrengruber MU, Clark-Lewis I, Baggiolini M, Rot A. Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin 8. Proc Natl Acad Sci USA 1993; 90: 7158-62.
39. Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 1998; 101: 877-89.
40. Wahl SM, Hunt DA, Wakefield LM, McCartney-Francis N, Wahl LM, Roberts B, Sporn MB. Transforming growth factor type β induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA 1987; 84: 5788-92.
41. Wahl SM, Allen JB, Weeks BS, Wong HL, Klotman PE. Transforming growth factor β enhances integrin expression and type IV collagenase secretion in human monocytes. Proc Natl Acad Sci USA 1993; 90: 4577-81.
42. Eddy AA, Warren J. Expression and function of monocyte chemoattractant protein-1 in experimental nephrotic syndrome. Clin Immunol Immunopathol 1996; 78: 140-51.
43. Eddy AA, McCulloch L, Liu E, Adams J. A relationship between proteinuria and acute tubulointerstitial disease in rats with experimental nephrotic syndrome. Am J Pathol 1991; 138: 1111-23.
44. Miyazano K, Olofsson A, Colosetti P, Heldin CH. A role of the latent TGF-β1 binding protein in the assembly and secretion of TGF-β1. EMBO J 1991; 10: 1091-101.
45. Hori Y, Katoh T, Hirakata M, Joki N, Kaname S, Fukagawa M, Okuda T, Ohashi H, Fujita T, Miyazono K, Kurokawa K. Anti-latent TGF-beta binding protein-1 antibody or synthetic oligopeptides inhibit extracellular matrix expression induced by stretch in cultured rat mesangial cells. Kidney Int 1998; 53: 1616-25.